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Background Kaposi's sarcoma in HIV antibody positive patients may affect the lungs. This study describes the presentation, chest radiographic appearances, and pulmonary function test abnormalities in patients with AIDS who had tracheobronchial Kaposi's sarcoma. Methods and results Twenty nine (8%) of 361 consecutive HIV antibody positive patients undergoing bronchoscopy for respiratory symptoms had tracheobronchial Kaposi's sarcoma. Eight patients had intercurrent infections and one had previously received chemotherapy for cutaneous Kaposi's sarcoma; these patients were excluded. Seven of the remaining 20 patients had localised Kaposi's sarcoma (lesions confined to the trachea or the subsegments of one lobe) and 13 had widespread Kaposi's sarcoma (affecting the trachea and one lobe or the subsegments of more than one lobe); 19 patients also had cutaneous and palatal Kaposi's sarcoma. Seven patients, four with widespread disease, had a normal radiograph. All patients had reduced transfer factor (TLCO) and transfer coefficient (Kco) but only those with widespread disease had reductions in forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and peak expiratory flow (PEF). Follow up pulmonary function testing in seven patients (median three months later) showed further reductions in TLCO. All Kaposi's sarcoma occurs in up to a quarter of patients with the acquired immunodeficiency syndrome (AIDS) and is particularly common in homosexual and bisexual men.' The most common site is the skin, where multiple lesions occur. Within the chest Kaposi's sarcoma may occur in the tracheobronchial tree, lung parenchyma, mediastinal lymph nodes, or visceral pleura.2 The exact incidence of intrathoracic Kaposi's sarcoma in patients with AIDS is unknown. In clinical studies pulmonary Kaposi's sarcoma has been reported in 3-13% of patients with AIDS23 and in up to 32% of patients with AIDS who had cutaneous Kaposi's sarcoma.245 In contrast, bronchopulmonary Kaposi's sarcoma was found at necropsy in 47% of patients with AIDS who had cutaneous Kaposi's sarcoma. 6 The diagnosis of pulmonary Kaposi's sarcoma may be difficult to make during life. Presenting symptoms and chest radiographic appearances are non-specific and non-invasive investigations, including exercise testing and arterial blood gas estimation, do not distinguish bronchopulmonary Kaposi In seven ofthe 20 patients the tracheobronchial Kaposi's sarcoma was localised and in 13 patients the lesions were widespread.
SYMPTOMS AND SIGNS
All 20 patients had cough and breathlessness, but no patient had chest pain or haemoptysis. The overall duration of symptoms ranged from one to 18 (median 4) weeks. In patients with widespread tracheobronchial Kaposi's sarcoma the duration of symptoms ranged from 1-18 (median = 4) weeks and in those with localised disease ranged from two to 12 (median 4) weeks (NS). Seventeen patients were cigarette smokers. Of seven patients with localised Kaposi's sarcoma, five had no previous respiratory episodes and two had prior pneumocystis pneumonia (three and 13 months previously). Ofthe 13 patients with widespread disease, five had no prior respiratory history, seven had pneumocystis pneumonia (median 14 (range 2-48) months previously) and one patient had had Streptococcus pneumoniae pneumonia eight months previously. The choice of treatment was based on consideration of many factors, including extent of cutaneous and pulmonary disease, intercurrent HIV related problems and patient preferences. Eleven patients, three with localised disease had no treatment. Nine patients received chemotherapy, three with epirubicin 10 mg IV once weekly, five with vincristine 2 mg IV and bleomycin 30 mg given intravenously once every three weeks (one patient also received radiotherapy to the mediastinum) and one, who was neutropenic, received bleomycin and radiotherapy to the mediastinum. Palliation of symptoms was achieved in all patients. Median survival for the whole group was 18 weeks (range 1-78 weeks).
RESULTS OF REPEAT PULMONARY FUNCTION TESTS
Follow up tests were performed in seven patients (of whom five also had repeat rebronchoscopy) two to six (median 3) months after the original investigations; at bronchoscopy no infections were identified. Four patients who received no treatment all had progressive cutaneous Kaposi's sarcoma and bronchoscopy in three showed progressive tracheobronchial disease. One patient had a stable chest radiograph; progressive abnormalities were seen in the other three. All four patients had further reductions in TLCO and in addition two also had further reductions in FEVy and FVC.
The three patients who received chemotherapy, despite palliation of symptoms, had further reductions in TLco; FEV, and FVC fell further in two patients. In one of these patients bronchoscopy showed regression of tracheobronchial disease and in the other the disease had progressed; the third patient showed no change.
HISTOLOGICAL DIAGNOSIS
Formal histological diagnosis was made in life in one patient by open lung biopsy three months after bronchoscopic diagnosis and at necropsy in a further seven patients. All seven patients had tracheobronchial lesions and lesions of the visceral pleura. Six also had parenchymal lesions and three had Kaposi's sarcoma of hilar and mediastinal lymph nodes.
Discussion
At presentation the duration of symptoms of cough and dyspnoea in our patients was variable and did not correlate with the extent of tracheobronchial Kaposi's sarcoma as assessed by bronchoscopy, the radiographic abnormalities, or the results of the lung function tests. In contrast to those in other studies, none ofour patients had chest pain or haemoptysis.6 7 We did not carry out bronchial or transbronchial biopsy, because of the low diagnostic yield and the attendant risks of haemorrhage. All but one patient had cutaneous and palatal Kaposi's sarcoma, which supported the diagnosis of tracheobronchial Kaposi's sarcoma, and a tissue diagnosis was made subsequently in eight of the patients who had this diagnosed at bronchoscopy. Occult alveolar haemorrhage was found in eight patients; this finding is thought to be specific for pulmonary Kaposi's sarcoma. In one study of HIV positive patients it was found in six of nine patients with pulmonary Kaposi's sarcoma and in none of 75 patients with other diagnoses, including tuberculosis.'2 Others have reported that occult alveolar haemorrhage is non-specific in HIV positive patients with respiratory symptoms, as in addition to occurring in patients with pulmonary Kaposi's sarcoma it was also found in patients with pneumocystis pneumonia, bacterial pneumonia, and mycobacterial infection.'0 Seven of our patients, including four with widespread tracheobronchial disease, had normal chest radiographs; this suggests that bronchoscopic assessment of the extent of tracheobronchial Kaposi's sarcoma does not accurately reflect the extent of parenchymal lesions.
There are few data on abnormalities of pulmonary function in HIV positive patients with pulmonary Kaposi's sarcoma. In one study 11 of 12 patients with pulmonary Kaposi's sarcoma, tested before chemotherapy, had a TLco below 80% of the predicted value, the mean TLCo being 64% (range 48-84%). All but one patient had multiple lesions of Kaposi's sarcoma seen at bronchoscopy, but the extent of the disease was not quantified. 5 In another study eight of eleven patients with pulmonary Kaposi's sarcoma (confirmed at necropsy) had visible tracheobronchial lesions at bronchoscopy. All patients had reductions in TLco but FVC was normal (>80% predicted) in eight patients. Six patients had evidence of airflow obstruction, which did not correlate with smoking history. Four of these six patients had tracheal or endobronchial Kaposi's sarcoma. Four other patients, who also had tracheal or bronchial Kaposi's sarcoma, did not have an obstructive pattern of results in pulmonary function tests.6 In this study eight patients had infections as well as Kaposi's sarcoma, P carinii in six and Haemophilis influenzae in one, which makes interpretation of the data on lung function unreliable.6 In a study of 16 patients with pulmonary Kaposi's sarcoma who had lesions visible at bronchoscopy TLCO was below 80% of predicted in three of nine patients tested (mean (SD) 78% (14-5%) predicted); the FVC was 73% (15-4%) predicted. In the same study 11 of 15 other patients with pulmonary Kaposi's sarcoma and coinfections, including pneumocystis pneumonia and mycobacterial infection, underwent pulmonary function testing. All these patients-had a TLCo below 80% predicted (mean (SD) 58% (9-8%)); FVC was 66% (21%) predicted. ' Follow up lung function testing in four patients who were not treated showed further reductions in TLCO and Kco. Surprisingly, despite deterioration of the chest radiograph in all four patients and bronchoscopic evidence of progression of tracheobroncial disease in three, only two patients had further reductions in FEV, and FVC. All three patients who received chemotherapy had palliation of symptoms, yet in two patients the chest radiograph deteriorated and in all three the TLCO fell. In one of these patients repeat bronchoscopy indicated that tracheobronchial disease had responded to treatment; yet FEV, FVC, and TLco had fallen. These results suggest that neither palliation of symptoms nor bronchoscopic improvement necessarily reflects the response of intrapulmonary Kaposi's sarcoma to chemotherapy.
In conclusion, pulmonary Kaposi's sarcoma produces abnormalities of TLco even in patients with localised tracheobronchial disease; in patients with widespread disease airflow obstruction may occur. If the disease is untreated, progressive abnormalities are seen on the chest radiograph and in the results of pulmonary function tests. Even though chemotherapy palliates symptoms, some patients have progressive abnormalities of lung function. Reassessment of the extent of disease by bronchoscopy may not accurately reflect the response to chemotherapy.
